EL PASO, TX--(Marketwired - Jul 6, 2016) - Premier Biomedical, Inc. (
William Hartman, President and CEO of Premier Biomedical, Inc., said, "At the start of these initial tests, we were hoping for comparable performance of our antibody versus competitive products, but we were delighted about the demonstrated superior performance of our immunotherapy anti-cancer drug PBI-5D3H5 in these initial tests. Testing also confirmed compatibility of our drug with human tissue. Further testing of our drug is underway and is expected to be concluded within the next several months. These test results reinforce the material presented at the American Association for Cancer Research Symposium earlier this year in New Orleans. When the next series of tests are concluded, major announcements regarding specific results will be released."
About Premier Biomedical, Inc.
Premier Biomedical, Inc. (
Safe Harbor Notice
Certain statements made in this news release constitute forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Premier Biomedical makes no guarantee of future performance and actual results could differ materially. Premier Biomedical, Inc. undertakes no obligation to revise or update these.
Contact Information:
Contact
William A. Hartman
President and CEO
(724) 633-7033
PR@premierbiomedical.com